CRVO
MCID: CNT016
MIFTS: 53

Central Retinal Vein Occlusion (CRVO)

Categories: Blood diseases, Cardiovascular diseases, Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Central Retinal Vein Occlusion

MalaCards integrated aliases for Central Retinal Vein Occlusion:

Name: Central Retinal Vein Occlusion 12 58 54 15 70
Crvo 58

Characteristics:

Orphanet epidemiological data:

58
central retinal vein occlusion
Prevalence: 1-5/10000 (Europe); Age of onset: Adult,Elderly;

Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:2450
ICD9CM 34 362.35
MeSH 44 D012170
NCIt 50 C118859
SNOMED-CT 67 193378003
ICD10 32 H34.81
ICD10 via Orphanet 33 H34.8
UMLS via Orphanet 71 C0154841
Orphanet 58 ORPHA411527
UMLS 70 C0154841

Summaries for Central Retinal Vein Occlusion

MalaCards based summary : Central Retinal Vein Occlusion, also known as crvo, is related to macular retinal edema and retinal vascular disease. An important gene associated with Central Retinal Vein Occlusion is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Ranibizumab and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are cystoid macular edema and macular cotton wool spot

Wikipedia : 73 Central retinal vein occlusion, also CRVO, is when the central retinal vein becomes occluded, usually... more...

Related Diseases for Central Retinal Vein Occlusion

Diseases in the Retinal Vein Occlusion family:

Central Retinal Vein Occlusion

Diseases related to Central Retinal Vein Occlusion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 507)
# Related Disease Score Top Affiliating Genes
1 macular retinal edema 32.1 VEGFA SERPINF1 IL6
2 retinal vascular disease 31.3 VEGFA SERPINF1 MTHFR IL6
3 intraocular pressure quantitative trait locus 31.2 VEGFA SERPINF1 LOXL1
4 retinal detachment 31.1 VEGFA SERPINF1 IL6
5 macular holes 31.1 VEGFA SERPINF1 IL6
6 vasculitis 31.0 VWF IL6 APOH
7 open-angle glaucoma 31.0 VEGFA MTHFR LOXL1 IL6
8 retinal vein occlusion 30.9 VEGFA SERPINF1 SERPINC1 MTHFR LOXL1 IL6
9 diabetic macular edema 30.7 VEGFA SERPINF1 IL6
10 arteritic anterior ischemic optic neuropathy 30.7 MTHFR F5 F2
11 hypopyon 30.6 VEGFA IL6
12 amaurosis fugax 30.6 MTHFR F5
13 branch retinal artery occlusion 30.6 VEGFA SERPINC1 MTHFR F3 F2 APOH
14 homocysteinemia 30.6 VWF SERPINC1 MTHFR F5 F2 APOH
15 central retinal artery occlusion 30.6 VEGFA SERPINC1 PLAT MTHFR F2
16 fainting 30.5 VWF F8
17 eclampsia 30.5 VEGFA SERPINC1 MTHFR F2
18 iritis 30.5 VEGFA IL6
19 microvascular complications of diabetes 1 30.5 VEGFA SERPINF1 IL6
20 exanthem 30.4 VEGFA IL6 F3 F2
21 migraine with or without aura 1 30.3 MTHFR IL6 F2 APOH
22 syphilis 30.3 IL6 F2 APOH
23 polycythemia 30.3 VEGFA SERPINC1 JAK2 F5 F2
24 protein s deficiency 30.3 SERPINC1 MTHFR F5 F3 F2 APOH
25 cavernous sinus thrombosis 30.3 SERPINC1 F3 F2
26 retinal artery occlusion 30.2 VEGFA SERPINC1 MTHFR IL6 F8 F5
27 papilledema 30.2 VEGFA SERPINC1 F3 F2 APOH
28 severe pre-eclampsia 30.2 VEGFA SERPINC1 F5 APOH
29 catastrophic antiphospholipid syndrome 30.2 MTHFR F5 F3 APOH
30 hemolytic-uremic syndrome 30.1 VWF F3 F2
31 carotid stenosis 30.1 VWF VEGFA MTHFR
32 nephrosclerosis 30.1 VEGFA MTHFR F3 F2
33 covid-19 30.1 VWF IL6 F3
34 eisenmenger syndrome 30.1 VWF PLAT
35 angina pectoris 30.0 PLAT IL6 F3
36 protein c deficiency 30.0 SERPINC1 MTHFR F5 F2 APOH
37 sneddon syndrome 29.9 SERPINC1 F8 F5 F2 APOH
38 purpura 29.9 VWF SERPINC1 IL6 F3 F2 APOH
39 hemoglobinuria 29.9 SERPINC1 G6PD F2
40 thrombotic thrombocytopenic purpura 29.8 VWF SERPINC1 PLAT F3 APOH
41 thrombophilia due to activated protein c resistance 29.8 VWF SERPINC1 MTHFR F8 F5 F3
42 cataract 29.8 VEGFA SERPINF1 MTHFR LOXL1 IL6 G6PD
43 compartment syndrome 29.7 SERPINC1 IL6 F8 F3 F2
44 intracranial hypertension 29.7 SERPINC1 MTHFR F5 F3 F2 APOH
45 nonarteritic anterior ischemic optic neuropathy 29.7 VEGFA SERPINC1 MTHFR G6PD F5 F2
46 factor xii deficiency 29.6 VWF SERPINC1 F5 F3 APOH
47 antithrombin iii deficiency 29.6 SERPINC1 MTHFR JAK2 F5 F2 APOH
48 atherosclerosis susceptibility 29.6 VWF VEGFA MTHFR IL6 F3
49 hemophilia b 29.5 VWF SERPINC1 F8 F3 F2
50 antiphospholipid syndrome 29.5 VWF SERPINC1 PLAT MTHFR F5 F3

Comorbidity relations with Central Retinal Vein Occlusion via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Central Retinal Vein Occlusion:



Diseases related to Central Retinal Vein Occlusion

Symptoms & Phenotypes for Central Retinal Vein Occlusion

Human phenotypes related to Central Retinal Vein Occlusion:

58 31 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 cystoid macular edema 58 31 hallmark (90%) Very frequent (99-80%) HP:0011505
2 macular cotton wool spot 58 31 hallmark (90%) Very frequent (99-80%) HP:0030497
3 intraretinal hemorrhage 58 31 hallmark (90%) Very frequent (99-80%) HP:0031805
4 visual loss 58 31 frequent (33%) Frequent (79-30%) HP:0000572
5 papilledema 58 31 frequent (33%) Frequent (79-30%) HP:0001085
6 retinal vascular tortuosity 58 31 frequent (33%) Frequent (79-30%) HP:0012841
7 glaucoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0000501
8 macular degeneration 58 31 occasional (7.5%) Occasional (29-5%) HP:0000608
9 pigmentary retinopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0000580
10 blurred vision 58 31 occasional (7.5%) Occasional (29-5%) HP:0000622
11 large central visual field defect 58 31 occasional (7.5%) Occasional (29-5%) HP:0001129
12 epiretinal membrane 58 31 occasional (7.5%) Occasional (29-5%) HP:0100014
13 abnormal anterior eye segment morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0004328
14 electronegative electroretinogram 58 31 occasional (7.5%) Occasional (29-5%) HP:0007984
15 retinal neovascularization 58 31 occasional (7.5%) Occasional (29-5%) HP:0030666
16 macular edema 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Central Retinal Vein Occlusion:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 APOH F2 F3 F5 F8 G6PD
2 cardiovascular system MP:0005385 10.29 F2 F3 F5 G6PD IL6 JAK2
3 growth/size/body region MP:0005378 10.22 F2 F3 F5 G6PD IL6 JAK2
4 hematopoietic system MP:0005397 10.16 F3 F8 G6PD IL6 JAK2 PLAT
5 mortality/aging MP:0010768 10.13 APOH F2 F3 F5 F8 G6PD
6 immune system MP:0005387 10.1 F2 F3 F8 IL6 JAK2 PLAT
7 digestive/alimentary MP:0005381 10.04 F2 IL6 LOXL1 PLAT SERPINF1 VEGFA
8 nervous system MP:0003631 10.03 F2 F3 F5 G6PD IL6 LOXL1
9 integument MP:0010771 10.02 F2 F3 F5 IL6 JAK2 LOXL1
10 reproductive system MP:0005389 9.85 F2 F8 IL6 JAK2 LOXL1 MTHFR
11 respiratory system MP:0005388 9.5 F2 F3 IL6 JAK2 LOXL1 PLAT
12 vision/eye MP:0005391 9.23 F3 IL6 LOXL1 MTHFR PLAT SERPINC1

Drugs & Therapeutics for Central Retinal Vein Occlusion

Drugs for Central Retinal Vein Occlusion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4 347396-82-1 459903
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
4
Lactitol Approved, Investigational Phase 4 585-86-4 157355
5 Dexamethasone 21-phosphate Phase 4
6 Angiogenesis Inhibitors Phase 4
7 Hormones Phase 4
8 Hormone Antagonists Phase 4
9 glucocorticoids Phase 4
10 Anti-Inflammatory Agents Phase 4
11 Gastrointestinal Agents Phase 4
12 Antiemetics Phase 4
13 Antineoplastic Agents, Hormonal Phase 4
14 BB 1101 Phase 4
15
Histidine Investigational, Nutraceutical Phase 4 71-00-1 6274
16
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
17
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
18
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
19
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
20
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
21
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
22
Bevacizumab Approved, Investigational Phase 3 216974-75-3
23
Povidone-iodine Approved Phase 3 25655-41-8
24
Povidone Approved Phase 3 9003-39-8 131751496
25
Iodine Approved, Investigational Phase 3 7553-56-2 807
26
Nicotinamide Approved, Investigational Phase 2, Phase 3 98-92-0 936
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
28
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3 59-67-6 938
29
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
30
Cadexomer iodine Experimental Phase 3 94820-09-4
31 insulin Phase 2, Phase 3
32 Insulin, Globin Zinc Phase 2, Phase 3
33 Triamcinolone diacetate Phase 3
34 Triamcinolone hexacetonide Phase 3
35 triamcinolone acetonide Phase 3
36 Protective Agents Phase 2, Phase 3
37 Immunosuppressive Agents Phase 3
38 Immunologic Factors Phase 3
39
protease inhibitors Phase 2, Phase 3
40 HIV Protease Inhibitors Phase 2, Phase 3
41 Methylprednisolone Acetate Phase 2, Phase 3
42 Neuroprotective Agents Phase 2, Phase 3
43 Mitogens Phase 3
44 Endothelial Growth Factors Phase 3
45 Antineoplastic Agents, Immunological Phase 3
46 Anti-Bacterial Agents Phase 3
47 Antibiotics, Antitubercular Phase 3
48 Antimetabolites Phase 2, Phase 3
49 Vasodilator Agents Phase 2, Phase 3
50 Micronutrients Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 82)
# Name Status NCT ID Phase Drugs
1 Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
2 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
3 Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES) Unknown status NCT01857544 Phase 4 Aflibercept
4 An Open-label, Multi-center, 6-month Extension Study Comparing the Long-term Efficacy and Safety of Lucentis (Ranibizumab) Intravitreal Injections Versus Ozurdex (Dexamethasone) Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) Who Have Completed the Respective Core Study (CRFB002EDE17 or CRFB002EDE18) Completed NCT01580020 Phase 4 Dexamethasone
5 Pilot Study on Efficacy and Tolerance of Intravitreous Injection of Ranibizumab (Lucentis®) in Early-onset Central Retinal Vein Occlusion in Comparison to Hemodilution Using Erythrocytapheresis Completed NCT01448018 Phase 4 ranibizumab
6 A Multi-center, Single-arm, Interventional Phase 4 Study to Evaluate a Treat and Extend Regimen of Intravitreal Aflibercept for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT02800642 Phase 4 Aflibercept (Eylea, BAY86-5321)
7 Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm Completed NCT02274259 Phase 4 Aflibercept;Ranibizumab
8 NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
9 The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion Completed NCT00557232 Phase 4 bevacizumab
10 A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months. Completed NCT01710839 Phase 4 0.5mg Ranibizumab
11 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema: The COLLIDE Trial Terminated NCT02684084 Phase 4 Ozurdex;Lucentis
12 Prospective, Randomised, Placebo-controlled, Double-masked, Three-armed Multi-centre Trial of Aganirsen Versus Vehicle in Patients After Ischaemic Central Retinal Vein Occlusion With a High Risk to Develop Neovascular Glaucoma Unknown status NCT02947867 Phase 2, Phase 3 aganirsen
13 An Efficacy and Safety Trial of Intravitreal Injection of Conbercept Ophthalmic Injection in Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT03223714 Phase 3 Conbercept Ophthalmic Injection;sham injection
14 A 3-month, Phase III, Open-label, Single Arm, Multicenter Study Assessing the Efficacy and Safety of 0.5 mg Ranibizumab Monthly Intravitreal Injections as Monotherapy in Patients With Visual Impairment Due to Macular Edema Secondary to Branch or Central Retinal Vein Occlusion (RVO) Completed NCT01377597 Phase 3 ranibizumab
15 A Prospective, Randomized, Controlled Study on Intravitreal Bevacizumab (Avastin) for Central Retinal Vein Occlusion (CRVO) Completed NCT00906685 Phase 3 bevacizumab;Sham bevacizumab injection
16 A Randomized Study Comparing the Safty Anf Efficacy of Ranibizumab (Lucentis®) to Sham in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO Completed NCT00567697 Phase 3 ranibizumab;ranibizumab
17 A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Central Retinal Vein Occlusion (CRVO) [Camellia] Completed NCT01976312 Phase 3 Ranibizumab 0.5 mg
18 A 6-month Multicenter, Randomized, Double-masked Phase IIIb-study Comparing the Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Central Retinal Vein Occlusion (CRVO) Completed NCT01396083 Phase 3 Ranibizumab;Dexamethasone implant and sham injections
19 Extended Follow-up of Patients With Macular Edema Due to bRanch rETinal Vein Occlusion (BRVO) or centrAl Retinal veIn occlusioN (CRVO) Previously Treated With Intravitreal Ranibizumab Completed NCT01198327 Phase 3 ranibizumab
20 A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
21 A Multicenter Trial for Surgical Treatment of Central Retinal Vein Occlusion - Radial Optic Neurotomy for CVO The ROVO Study Completed NCT00532142 Phase 2, Phase 3 Intravitreal Triamcinolone
22 A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT00943072 Phase 3 Sham
23 Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab Therapy for Non-Ischemic Central Retinal Vein Occlusion Completed NCT01295112 Phase 2, Phase 3 Active bevacizumab and Sham dexamethasone;Active bevacizumab and Active dexamethasone
24 A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT00485836 Phase 3 Sham injection;Ranibizumab injection 0.3 mg;Ranibizumab injection 0.5 mg
25 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema Completed NCT00105027 Phase 3 intravitreal triamcinolone injection;intravitreal triamcinolone injection
26 Niacin (as a Vasodilator), and a Topical Steroid (for Macular Edema), Non-Ischemic CRVO,HRVO,BRVO Completed NCT00493064 Phase 2, Phase 3 Nicotinic acid;Prednisolone acetate
27 Intravitreal Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Recruiting NCT04460001 Phase 2, Phase 3 Ranibizumab;Ranibizumab;triamcinolone acetate
28 An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion Recruiting NCT03810313 Phase 3 Brolucizumab 6 mg;Aflibercept 2 mg
29 Long-term Need of Ranibizumab Injections With or Without Early Targeted Peripheral Laser Photocoagulation for Treatment of Macular Edema Due to Central Retinal Vein Occlusion Recruiting NCT04444492 Phase 3 Ranibizumab Injection
30 Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks. Active, not recruiting NCT01969708 Phase 3 aflibercept;bevacizumab
31 Randomized Trial of Intravitreous Aflibercept Versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema Active, not recruiting NCT03321513 Phase 3 intravitreous aflibercept;Bevacizumab + Deferred Aflibercept Group
32 "Retrospective Study of Niacin (as a Vasodilator), Combined With a Topical Steroid (for Macular Edema), For CRVO, HRVO, BRVO." Terminated NCT00500045 Phase 2, Phase 3 nicotinic acid
33 Does Hyperbaric Chamber Improve the Functionality and Symptoms Related to Central Retinal Vein Occlusion (CRVO)? Unknown status NCT02405741 Phase 2
34 Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO) Unknown status NCT00370630 Phase 2 Avastin (Bevacizumab) and triamcinolone
35 Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion Unknown status NCT01178697 Phase 2 Bevasizumab;Triamcinolone Acetonide
36 Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment. Unknown status NCT02957760 Phase 2 Hydroxycarbamid
37 A Randomized, Controlled, Two-center Phase II Study Assessing the Efficacy and Safety of Intravitreal Lucentis Injections in Patients With Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT01123564 Phase 2 ranibizumab
38 Open Label Squalamine Lactate Ophthalmic Solution for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO) Completed NCT02614937 Phase 1, Phase 2 ranibizumab;Squalamine Lactate Ophthalmic Solution, 0.2%
39 Safety and Efficacy of Ziv Aflibercept in Myopic Choroidal Neovascularisation ,Central Retinal Vein Occlusion and Resistant Diabetic Macular Edema Completed NCT04290195 Phase 1, Phase 2 Ziv-Aflibercept 25 MG/ML [Zaltrap]
40 A Single-center, Open-label Study Evaluating the Impact of Repeat Intravitreal Injections of Aflibercept on Capillary Non-Perfusion (CNP) in Subjects With Proliferative Retinopathy and/or Macular Edema Secondary to Proliferative Diabetic Retinopathy and Central Retinal Venous Occlusive Disease Completed NCT01724554 Phase 1, Phase 2 Intravitreal Aflibercept Injection
41 Phase I/II Trial of TLC399 (ProDex) in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) Completed NCT02006147 Phase 1, Phase 2 TLC399
42 A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Central Retinal Vein Occlusions Completed NCT01468844 Phase 1, Phase 2 Minocycline;Placebo;Bevacizumab
43 A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary to CRVO Completed NCT00088283 Phase 2 pegaptanib sodium
44 Phase I/II Randomized, Prospective, Double-masked, Sham-controlled Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Central Retinal Vein Occlusion Recruiting NCT03981549 Phase 1, Phase 2
45 A Randomized, Double Masked, Multicenter, Phase II Study Assessing the Safety and Efficacy of 601 Versus Ranibizumab in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Not yet recruiting NCT04667910 Phase 2 601 1.25mg;Ranibizuman 0.5 mg
46 Randomized Controlled Trial of Lucentis in the Management of New Onset Neovascular Glaucoma Withdrawn NCT00727038 Phase 1, Phase 2 Ranibizumab (Lucentis)
47 Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema (COLLIDE) Withdrawn NCT03629210 Phase 2 OZURDEX
48 Ziv-aflibercept in Eyes With Eyes With Retinal Diseases and Poor Vision-phase I Unknown status NCT02173873 Phase 1 ziv-aflibercept drug
49 Phase 1 Trial of Intra-Ophthalmic Artery Thrombolysis for Treating Recent Severe Central Retinal Vein Occlusion Completed NCT01581411 Phase 1 Tissue Plasminogen Activator
50 Phase Ib Study on Surgical Stabilizer Assisted Retinal Vein Cannulation With tPA Infusion Confirmed by Intraoperative Angio-OCT for the Treatment of CRVO Completed NCT03417401 Phase 1 Intravenous Infusion

Search NIH Clinical Center for Central Retinal Vein Occlusion

Genetic Tests for Central Retinal Vein Occlusion

Anatomical Context for Central Retinal Vein Occlusion

MalaCards organs/tissues related to Central Retinal Vein Occlusion:

40
Eye, Retina, Endothelial, Heart, Myeloid, Bone Marrow, Bone

Publications for Central Retinal Vein Occlusion

Articles related to Central Retinal Vein Occlusion:

(show top 50) (show all 2321)
# Title Authors PMID Year
1
Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. 61 54
19967679 2010
2
Comparison of surgical treatments for central retinal vein occlusion; RON vs. cannulation of tissue plasminogen activator into the retinal vein. 54 61
19734765 2009
3
Central retinal vein occlusion secondary to clomiphene treatment in a male carrier of factor V Leiden. 61 54
19371211 2009
4
Central retinal vein occlusion with therapeutic level of anticoagulation. 54 61
19707484 2009
5
Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. 54 61
19118700 2009
6
Anticoagulant therapy after retinal vein occlusion in patients with protein S deficiency (Protein S deficiency with homozygous factor V Leiden mutation in central retinal vein occlusion. Vol. 42[4]). 54 61
18059510 2007
7
Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion. 61 54
18040240 2007
8
Treatment of total exudative retinal detachment due to central retinal vein occlusion by intravitreal bevacizumab in a patient with p-ANCA vasculitis. 54 61
19668494 2007
9
Protein S deficiency with homozygous factor V Leiden mutation in central retinal vein occlusion. 54 61
17641719 2007
10
Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. 61 54
17700285 2007
11
[Recurrent incomplete central retinal vein occlusion in a patient with hereditary thrombophilia]. 54 61
16848214 2006
12
Endophthalmitis with retinal necrosis following intravitreal triamcinolone acetonide injection. 61 54
16491037 2006
13
[Central retinal vein occlusion in a factor V leiden and G21210A prothrombin variant carrier]. 61 54
15389368 2004
14
Hyperhomocysteinemia and the methylenetetrahydrofolate reductase 677C-T mutation in patients under 50 years of age affected by central retinal vein occlusion. 61 54
15121372 2004
15
Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion. 61 54
14707827 2003
16
Central retinal vein occlusion and renal cell carcinoma. 61 54
14644245 2003
17
Hyperhomocysteinemia in central retinal vein occlusion in young adults. 61 54
15513477 2003
18
Influence of factor V Leiden on the development of neovascularisation secondary to central retinal vein occlusion. 61 54
12598443 2003
19
Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. 54 61
12470137 2002
20
Treatment of central retinal vein occlusion by vitrectomy with lysis of vitreopapillary and epipapillary adhesions, subretinal peripapillary tissue plasminogen activator injection, and photocoagulation. 61 54
12383824 2002
21
Recurrent central retinal vein occlusion in a young thrombophilic patient with factor V Leiden mutation. 61 54
12022286 2002
22
Simultaneous bilateral central retinal vein occlusion associated with anticardiolipin antibodies in leukemia. 54 61
11476696 2001
23
Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion. 61 54
11797310 2001
24
Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion. 61 54
11321143 2001
25
Activated protein C resistance is a risk factor for central retinal vein occlusion. 61 54
11059059 2000
26
Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. 54 61
10837386 2000
27
Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion. 54 61
10634550 1999
28
Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. 54 61
10634554 1999
29
[Activated protein C resistance in patients with central retinal vein occlusion in comparison to patients with a history of deep-vein thrombosis and a healthy control group]. 61 54
10501988 1999
30
Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. 54 61
10392729 1999
31
Risk factors in central retinal vein occlusion and activated protein C resistance. 54 61
10230591 1999
32
Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults. 61 54
9596492 1998
33
Vascular endothelial growth factor upregulation in human central retinal vein occlusion. 61 54
9499769 1998
34
Bilateral retinal vein occlusion associated with 5,10-methylenetetrahydrofolate reductase mutation. 54 61
9402832 1997
35
Screening for resistance to activated protein C and the mutant gene for factor V:Q506 in patients with central retinal vein occlusion. 61 54
9372721 1997
36
Activated protein C resistance in patients with central retinal vein occlusion. 61 54
9486021 1997
37
Activated protein C resistance in central retinal vein occlusion. 54 61
9059288 1996
38
Activated protein C resistance--low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion. 54 61
8913121 1996
39
Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. 61 54
8703856 1996
40
Activated protein C resistance in young adults with central retinal vein occlusion. 61 54
8703855 1996
41
Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. 54 61
8981710 1996
42
Hypoxic regulation of vascular endothelial growth factor in retinal cells. 61 54
7487623 1995
43
Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. 54 61
7540233 1995
44
Factor V and antithrombin gene mutations in patients with idiopathic central retinal vein occlusion. 54 61
8849546 1995
45
Choroidal thickening in retinal vein occlusion patients with serous retinal detachment. 61
33205242 2021
46
AQUEOUS HUMOR CYTOKINE LEVELS AND REBOUND MACULAR EDEMA AFTER CONBERCEPT TREATMENT IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION. 61
33755650 2021
47
Central retinal vein occlusion in the setting of COVID-19 infection. 61
33796944 2021
48
Closure of macular hole secondary to ischemic hemi-central retinal vein occlusion by retinal photocoagulation and topical anti-inflammatory treatment. 61
32827075 2021
49
Changes in venous calibre during intra-vitreal therapy for central retinal vein occlusion. 61
32415187 2021
50
Real-life study of the use of anti-VEGF therapy versus dexamethasone implant for treatment of macular edema in retinal vein occlusion. 61
33738625 2021

Variations for Central Retinal Vein Occlusion

Expression for Central Retinal Vein Occlusion

Search GEO for disease gene expression data for Central Retinal Vein Occlusion.

Pathways for Central Retinal Vein Occlusion

Pathways related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.93 VWF VEGFA SERPINC1 PLAT JAK2 F8
2
Show member pathways
12.53 SERPINC1 LOXL1 F8 F5 F3 F2
3
Show member pathways
12 PLAT MTHFR IL6 F2
4
Show member pathways
11.7 VWF SERPINC1 PLAT F8 F5 F3
5 11.64 VEGFA JAK2 IL6
6 11.56 VEGFA JAK2 IL6 F3
7 11.33 VWF SERPINC1 PLAT F8 F5 F3
8 10.74 VEGFA JAK2
9 10.69 VEGFA PLAT

GO Terms for Central Retinal Vein Occlusion

Cellular components related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 VWF VEGFA SERPINF1 SERPINC1 PLAT LOXL1
2 endoplasmic reticulum lumen GO:0005788 9.72 SERPINC1 IL6 F8 F5 F2
3 platelet alpha granule lumen GO:0031093 9.56 VWF VEGFA F8 F5
4 collagen-containing extracellular matrix GO:0062023 9.56 VWF SERPINF1 SERPINC1 PLAT LOXL1 F3
5 extracellular space GO:0005615 9.4 VWF VEGFA SERPINF1 SERPINC1 PLAT LOXL1
6 platelet alpha granule GO:0031091 9.37 VWF F5

Biological processes related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.84 VEGFA JAK2 IL6 F3
2 cellular protein metabolic process GO:0044267 9.73 SERPINC1 IL6 F5 F2
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.7 VEGFA JAK2 IL6
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.69 VEGFA JAK2 F2
5 platelet activation GO:0030168 9.67 VWF IL6 F8 F2
6 platelet degranulation GO:0002576 9.65 VWF VEGFA F8 F5 APOH
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 VEGFA JAK2 IL6
8 fibrinolysis GO:0042730 9.58 PLAT F2
9 acute-phase response GO:0006953 9.58 IL6 F8 F2
10 interleukin-6-mediated signaling pathway GO:0070102 9.57 JAK2 IL6
11 positive regulation of blood coagulation GO:0030194 9.56 F2 APOH
12 positive regulation of positive chemotaxis GO:0050927 9.55 VEGFA F3
13 regulation of blood coagulation GO:0030193 9.5 SERPINC1 F2 APOH
14 plasminogen activation GO:0031639 9.49 PLAT APOH
15 negative regulation of fibrinolysis GO:0051918 9.48 F2 APOH
16 blood coagulation, intrinsic pathway GO:0007597 9.46 VWF F8 F2 APOH
17 hemostasis GO:0007599 9.43 VWF SERPINC1 F8 F5 F3 F2
18 blood coagulation GO:0007596 9.23 VWF SERPINC1 PLAT JAK2 F8 F5

Molecular functions related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.33 VWF SERPINC1 F3
2 copper ion binding GO:0005507 9.13 LOXL1 F8 F5
3 heparin binding GO:0008201 8.92 VEGFA SERPINC1 F2 APOH

Sources for Central Retinal Vein Occlusion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....